IL149496A0 - Pharmaceutical combinations and their use in treating gastrointestinal disorders - Google Patents

Pharmaceutical combinations and their use in treating gastrointestinal disorders

Info

Publication number
IL149496A0
IL149496A0 IL14949600A IL14949600A IL149496A0 IL 149496 A0 IL149496 A0 IL 149496A0 IL 14949600 A IL14949600 A IL 14949600A IL 14949600 A IL14949600 A IL 14949600A IL 149496 A0 IL149496 A0 IL 149496A0
Authority
IL
Israel
Prior art keywords
gastrointestinal disorders
pharmaceutical combinations
treating gastrointestinal
treating
pharmaceutical
Prior art date
Application number
IL14949600A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL149496A0 publication Critical patent/IL149496A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14949600A 1999-12-10 2000-12-08 Pharmaceutical combinations and their use in treating gastrointestinal disorders IL149496A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45838899A 1999-12-10 1999-12-10
PCT/EP2000/012420 WO2001041748A2 (en) 1999-12-10 2000-12-08 Pharmaceutical combinations and their use in treating gastrointestinal disorders

Publications (1)

Publication Number Publication Date
IL149496A0 true IL149496A0 (en) 2002-11-10

Family

ID=23820591

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14949600A IL149496A0 (en) 1999-12-10 2000-12-08 Pharmaceutical combinations and their use in treating gastrointestinal disorders
IL149496A IL149496A (en) 1999-12-10 2002-05-06 Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL149496A IL149496A (en) 1999-12-10 2002-05-06 Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract

Country Status (30)

Country Link
EP (3) EP1488788A1 (de)
JP (1) JP2003523324A (de)
KR (1) KR100765579B1 (de)
CN (2) CN1875966A (de)
AR (1) AR026916A1 (de)
AT (1) ATE293971T1 (de)
AU (2) AU778869B2 (de)
BR (1) BR0016275A (de)
CA (1) CA2388959A1 (de)
CO (1) CO5261535A1 (de)
CZ (1) CZ300690B6 (de)
DE (1) DE60019814T2 (de)
DK (1) DK1286668T3 (de)
ES (1) ES2240229T3 (de)
HU (1) HUP0301122A3 (de)
IL (2) IL149496A0 (de)
MX (1) MXPA02005695A (de)
MY (1) MY133423A (de)
NO (1) NO20022680L (de)
NZ (2) NZ566800A (de)
PE (1) PE20011030A1 (de)
PL (1) PL202201B1 (de)
PT (1) PT1286668E (de)
RU (1) RU2264215C2 (de)
SG (1) SG152025A1 (de)
SK (1) SK8062002A3 (de)
TR (1) TR200402293T2 (de)
TW (1) TWI263496B (de)
WO (1) WO2001041748A2 (de)
ZA (1) ZA200204493B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284732A2 (de) * 2000-05-18 2003-02-26 Glaxo Group Limited Verfahren zur behandlung von funktionaler dyspepsie mit alosetron
GB0209481D0 (en) * 2002-04-24 2002-06-05 Novartis Ag Organic compounds
AU2004204827B2 (en) 2003-01-13 2006-06-29 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
MXPA05012463A (es) * 2003-05-27 2006-01-30 Altana Pharma Ag Combinaciones farmaceuticas de un inhibidor de bomba protonica y un compuesto que modifica la motilidad gastrointestinal.
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
US7820690B2 (en) 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
MX2007000507A (es) * 2004-07-14 2007-03-08 Novartis Ag Combinacion de inhibidores de dpp-iv y compuestos que modulan a los receptores 5-ht3 y/o 5-ht4.
BRPI0606898A2 (pt) * 2005-01-31 2009-07-21 Novartis Ag uso de agonista de 5-ht4 na preparação de medicamentos e método útil no esvaziamento gástrico retardado
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
WO2007085357A1 (en) 2006-01-30 2007-08-02 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
AU2007257652A1 (en) * 2006-06-15 2007-12-21 Novartis Ag Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury
EP2118080B1 (de) 2007-02-09 2016-08-31 Ocera Therapeutics, Inc. Makrocyclische ghrelin-rezeptormodulatoren und verwendungsverfahren dafür
WO2009064819A2 (en) * 2007-11-13 2009-05-22 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
US20090123390A1 (en) 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
TWI760352B (zh) 2016-08-09 2022-04-11 英商克馬伯有限公司 抗ｉｃｏｓ抗體
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
WO2022243378A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
CA2126354C (en) * 1991-12-21 2006-07-11 Gareth John Sanger Use of 5-ht4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
RU2264215C2 (ru) 2005-11-20
NZ566800A (en) 2009-11-27
SK8062002A3 (en) 2003-04-01
JP2003523324A (ja) 2003-08-05
CN1409634A (zh) 2003-04-09
ATE293971T1 (de) 2005-05-15
KR20030016208A (ko) 2003-02-26
TR200402293T2 (tr) 2004-10-21
BR0016275A (pt) 2002-08-27
ES2240229T3 (es) 2005-10-16
AU2005200797B2 (en) 2008-01-24
PL355663A1 (en) 2004-05-04
CZ300690B6 (cs) 2009-07-15
NO20022680L (no) 2002-08-12
CZ20021967A3 (cs) 2002-08-14
PE20011030A1 (es) 2001-10-31
NO20022680D0 (no) 2002-06-06
PL202201B1 (pl) 2009-06-30
DE60019814D1 (de) 2005-06-02
CA2388959A1 (en) 2001-06-14
IL149496A (en) 2009-12-24
HUP0301122A3 (en) 2005-03-29
MXPA02005695A (es) 2002-09-18
DK1286668T3 (da) 2005-08-15
HUP0301122A2 (hu) 2003-08-28
EP1488788A1 (de) 2004-12-22
EP1286668A2 (de) 2003-03-05
KR100765579B1 (ko) 2007-10-09
EP1286668B1 (de) 2005-04-27
NZ531489A (en) 2005-09-30
AU2672801A (en) 2001-06-18
CO5261535A1 (es) 2003-03-31
ZA200204493B (en) 2003-09-29
WO2001041748A2 (en) 2001-06-14
CN1310644C (zh) 2007-04-18
AU778869B2 (en) 2004-12-23
DE60019814T2 (de) 2006-03-02
AU2005200797A1 (en) 2005-03-17
SG152025A1 (en) 2009-05-29
MY133423A (en) 2007-11-30
EP1913944A1 (de) 2008-04-23
TWI263496B (en) 2006-10-11
PT1286668E (pt) 2005-08-31
CN1875966A (zh) 2006-12-13
WO2001041748A3 (en) 2002-12-19
AR026916A1 (es) 2003-03-05
RU2002118316A (ru) 2004-02-20

Similar Documents

Publication Publication Date Title
IL149496A0 (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
EP0924983A4 (de) S(-)-tolterodin in der behandlung urinärer und gastrointestinaler störungen
HK1062914A1 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
IL144954A0 (en) Quinazolines and therapeutic use thereof
HUP0203430A3 (en) Quinazolinones and their use
HUP0200548A2 (hu) Gyógyszerészeti készítmények és alkalmazásuk
GB9721437D0 (en) Heteroaromatic compounds and their use in medicine
HUP0400069A3 (en) Pharmaceutical combinations and their use in preventing and treating the thrombosis
SI1143997T1 (en) Tumor necrosis factor antagonists and their use in endometriosis treatment
ZA97741B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders.
AU2001266229A1 (en) Hcn polypeptides and polynucleotides and their use in therapy
AU2002243363A8 (en) Use of aziridino-compounds in the treatment of immune dysfunctions
HUP0301553A3 (en) Pharmaceutical compositions and their use for treating neurological disorders
PL363048A1 (en) Azabicyclic derivatives and their therapeutic use
HUP0105351A3 (en) Effervescent laxatives and their use
HK1053266A1 (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
SI1286668T1 (en) Pharmaceutical combinations comprising tegaserod und omeprazole and their use in treating gastrointestinal disorders
AU6330300A (en) Use of interleukin-6 in treatment of obesity and/or obesity associated disorders
EP1244467A4 (de) Phospholglyerat-kinase zur behandlung von krankheiten
GB9929581D0 (en) Comjpositions and their use
GB9903919D0 (en) Aminophenols and their therapeutic use
HUP0201800A2 (en) Novel calpains and their use
HUP9900045A3 (en) Improved leukaemic blood-based product and their use in therapy
GB0026428D0 (en) Hydroimidazolone derivatives and their use in therapy